Semaglutide for kidney disease in adults with type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have type 1 diabetes
- You’ve had type 1 diabetes for at least 5 years
- Your urine test shows ongoing kidney damage (UACR at least 30 mg/g) on the last two results within 3 years
- Your kidney filtration is reduced but not too low (eGFR at least 20 mL/min/1.73m²)
- Your blood pressure and cholesterol medicines are stable for at least 4 weeks before starting, and you’ll keep them stable during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a weekly semaglutide injection (a GLP-1 drug) to a closed-loop insulin system can help reduce the need for carb counting in people with type 1 diabetes. It aims to improve blood sugar control and make diabetes management easier.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This study tests whether an oral medication called semaglutide can help people with type 2 diabetes, fatty liver, and kidney problems. It aims to see if it can improve kidney function and liver health.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
This study looks at whether semaglutide (a diabetes medication) affects belly fat and the liver in people who have both type 2 diabetes and chronic kidney disease. It aims to understand if the drug can improve these health markers even in patients with reduced kidney function.
This trial tests whether the medication semaglutide (often used for diabetes) can prevent the development of new diabetes after a kidney transplant. If you are in the early weeks after a transplant and have risk factors for diabetes, this study might help reduce your chances of developing diabetes later.
Hear when a new Diabetic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.